301 related articles for article (PubMed ID: 7831322)
1. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis.
Griffiths RJ; Pettipher ER; Koch K; Farrell CA; Breslow R; Conklyn MJ; Smith MA; Hackman BC; Wimberly DJ; Milici AJ
Proc Natl Acad Sci U S A; 1995 Jan; 92(2):517-21. PubMed ID: 7831322
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the pharmacological profile of the potent LTB4 antagonist CP-105,696 on murine LTB4 receptors in vitro.
Showell HJ; Breslow R; Conklyn MJ; Hingorani GP; Koch K
Br J Pharmacol; 1996 Mar; 117(6):1127-32. PubMed ID: 8882606
[TBL] [Abstract][Full Text] [Related]
3. The in vitro and in vivo pharmacologic activity of the potent and selective leukotriene B4 receptor antagonist CP-105696.
Showell HJ; Pettipher ER; Cheng JB; Breslow R; Conklyn MJ; Farrell CA; Hingorani GP; Salter ED; Hackman BC; Wimberly DJ
J Pharmacol Exp Ther; 1995 Apr; 273(1):176-84. PubMed ID: 7714764
[TBL] [Abstract][Full Text] [Related]
4. Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228: impact upon leukotriene B4- and 12(R)-HETE-mediated events.
Fretland DJ; Anglin CP; Bremer M; Isakson P; Widomski DL; Paulson SK; Docter SH; Djuric SW; Penning TD; Yu S
Inflammation; 1995 Apr; 19(2):193-205. PubMed ID: 7601505
[TBL] [Abstract][Full Text] [Related]
5. (+)-1-(3S,4R)-[3-(4-phenylbenzyl)-4-hydroxychroman-7-yl]cyclopentane carboxylic acid, a highly potent, selective leukotriene B4 antagonist with oral activity in the murine collagen-induced arthritis model.
Koch K; Melvin LS; Reiter LA; Biggers MS; Showell HJ; Griffiths RJ; Pettipher ER; Cheng JB; Milici AJ; Breslow R
J Med Chem; 1994 Sep; 37(20):3197-9. PubMed ID: 7932545
[No Abstract] [Full Text] [Related]
6. The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543.
Showell HJ; Conklyn MJ; Alpert R; Hingorani GP; Wright KF; Smith MA; Stam E; Salter ED; Scampoli DN; Meltzer S; Reiter LA; Koch K; Piscopio AD; Cortina SR; Lopez-Anaya A; Pettipher ER; Milici AJ; Griffiths RJ
J Pharmacol Exp Ther; 1998 Jun; 285(3):946-54. PubMed ID: 9618393
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
Jackson WT; Froelich LL; Boyd RJ; Schrementi JP; Saussy DL; Schultz RM; Sawyer JS; Sofia MJ; Herron DK; Goodson T; Snyder DW; Pechous PA; Spaethe SM; Roman CR; Fleisch JH
J Pharmacol Exp Ther; 1999 Jan; 288(1):286-94. PubMed ID: 9862783
[TBL] [Abstract][Full Text] [Related]
8. Leukotriene B4-induced granulocyte trafficking in guinea pig dermis. Effect of second-generation leukotriene B4 receptor antagonists, SC-50605 and SC-51146.
Fretland DJ; Widomski DL; Anglin CP; Penning TD; Yu S; Djuric SW
Inflammation; 1993 Jun; 17(3):353-60. PubMed ID: 8392493
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration.
Liston TE; Conklyn MJ; Houser J; Wilner KD; Johnson A; Apseloff G; Whitacre C; Showell HJ
Br J Clin Pharmacol; 1998 Feb; 45(2):115-21. PubMed ID: 9491823
[TBL] [Abstract][Full Text] [Related]
10. Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist.
Marder P; Sawyer JS; Froelich LL; Mann LL; Spaethe SM
Biochem Pharmacol; 1995 May; 49(11):1683-90. PubMed ID: 7786309
[TBL] [Abstract][Full Text] [Related]
11. Effect of a leukotriene B4 receptor antagonist on leukotriene B4-induced neutrophil chemotaxis in cavine dermis.
Fretland DJ; Widomski DL; Zemaitis JM; Djurić SW; Shone RL
Inflammation; 1989 Oct; 13(5):601-5. PubMed ID: 2553605
[TBL] [Abstract][Full Text] [Related]
12. Involvement of leukotriene B4 in murine dermatitis models.
Tsuji F; Miyake Y; Horiuchi M; Mita S
Biochem Pharmacol; 1998 Feb; 55(3):297-304. PubMed ID: 9484795
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.
Sarau HM; Foley JJ; Schmidt DB; Martin LD; Webb EF; Tzimas MN; Breton JJ; Chabot-Fletcher M; Underwood DC; Hay DW; Kingsbury WD; Chambers PA; Pendrak I; Jakas DR; Sathe GM; Van Horn S; Daines RA; Griswold DE
Prostaglandins Leukot Essent Fatty Acids; 1999 Jul; 61(1):55-64. PubMed ID: 10477044
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the interaction of leukotriene b4 with its receptor prevents development of autoimmune uveitis.
Liao T; Ke Y; Shao WH; Haribabu B; Kaplan HJ; Sun D; Shao H
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1543-9. PubMed ID: 16565390
[TBL] [Abstract][Full Text] [Related]
15. The leukotriene B
Deng B; Lin Y; Ma S; Zheng Y; Yang X; Li B; Yu W; Xu Q; Liu T; Hao C; He R; Ding F
Kidney Int; 2017 Jul; 92(1):89-100. PubMed ID: 28318626
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma.
Turner CR; Breslow R; Conklyn MJ; Andresen CJ; Patterson DK; Lopez-Anaya A; Owens B; Lee P; Watson JW; Showell HJ
J Clin Invest; 1996 Jan; 97(2):381-7. PubMed ID: 8567958
[TBL] [Abstract][Full Text] [Related]
17. 20-Hydroxy- and 20-carboxy-leukotriene (LT) B
Archambault AS; Poirier S; Lefebvre JS; Robichaud PP; Larose MC; Turcotte C; Martin C; Provost V; Boudreau LH; McDonald PP; Laviolette M; Surette ME; Flamand N
J Leukoc Biol; 2019 Jun; 105(6):1131-1142. PubMed ID: 30676680
[TBL] [Abstract][Full Text] [Related]
18. The in vitro pharmacology of SC-51146: a potent antagonist of leukotriene B4 receptors.
Tsai BS; Keith RH; Villani-Price D; Kachur JF; Yang DC; Djuric SW; Yu S
J Pharmacol Exp Ther; 1994 Mar; 268(3):1499-505. PubMed ID: 8138960
[TBL] [Abstract][Full Text] [Related]
19. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice.
Aiello RJ; Bourassa PA; Lindsey S; Weng W; Freeman A; Showell HJ
Arterioscler Thromb Vasc Biol; 2002 Mar; 22(3):443-9. PubMed ID: 11884288
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of a novel, orally active leukotriene B4 antagonist, SM-15178.
Ohmi N; Tani C; Yamada K; Fukui M
Inflammation; 1994 Apr; 18(2):129-40. PubMed ID: 8070898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
